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Fibrinolytic activity of human mesothelial cells is counteracted by rapid surface area of the mesothelium between the peritoneal
uptake of tissue-type plasminogen activator. cavity and the circulatory system. In addition to being
Background. Human mesothelial cells (HMCs) have an important
an active permeability barrier during CAPD, the meso-role in maintaining an adequately functioning fibrinolytic system in
the peritoneal cavity by secreting the fibrinolytic enzymes tissue-type thelium has an important role in maintaining an adequate
and urokinase-type plasminogen activator (t-PA and u-PA), as well fibrinolytic capacity in the peritoneal cavity. This plasma-as a specific PA inhibitor, PA inhibitor type 1 (PAI-1). In this study,
independent fibrinolytic system is crucial in the dissolu-we investigated whether the fibrinolytic capacity of HMCs is further
counterbalanced by rapid uptake of t-PA and u-PA from the medium. tion of fibrous exudates and in preventing the formation
Methods. Cultured HMCs were used to study the uptake and degra- of fibrinous peritoneal adhesions [1, 2]. When the localdation of radiolabeled t-PA and u-PA in the absence or presence of
fibrinolytic activity is insufficient, for example, duringan inhibitor of cellular protein degradation, chloroquine, and of specific
receptor antagonists. Northern blotting and ligand-blotting techniques physical and chemical irritation of the peritoneum through
were applied to demonstrate the presence of specific receptors for CAPD, persistence of fibrin and organization of the fi-binding of t-PA and u-PA.
brinous adhesions may occur [3, 4]. It has been shownResults. At 378C, HMCs rapidly internalized and degraded 125I-t-PA
and 125I-u-PA, which could be inhibited by an excess of unlabeled t-PA that experimentally-induced peritoneal adhesions can be
and u-PA, respectively, and by the lysosomotropic agent chloroquine. prevented by intraperitoneal application of exogenousNorthern blot analysis showed the expression of low-density lipopro-
tein (LDL) receptor–related protein (LRP), very low density lipopro- initiators of fibrinolysis, such as tissue-type plasminogen
tein (VLDL) receptor, and u-PA receptor. The addition of recombinant activator (t-PA) or streptokinase [5, 6]. However, little
39 kDa receptor-associated protein (RAP; an inhibitor of LRP and
is known about the physiological regulation of the fibrino-VLDL receptor) almost completely blocked the degradation of t-PA
and partly that of u-PA. RAP ligand blotting demonstrated predomi- lytic activity in the peritoneum.
nantly the presence of LRP, suggesting a major role for the LRP in Mesothelial cells make up the major cell population
mediating uptake and degradation of t-PA in HMCs. Endocytosis of
that lines the peritoneal cavity. Cultured human meso-u-PA occurs via two different pathways. After binding to u-PA recep-
tor, a RAP-inhibitable and a non-RAP-inhibitable route for u-PA thelial cells (HMCs) have been shown to produce large
degradation was demonstrated. Tumor necrosis factor a (TNFa) dimin- amounts of PAs, t-PA, and urokinase-type PA (u-PA), as
ished the fibrinolytic activity of HMCs by decreasing t-PA and increas-
well as their specific inhibitor, PA inhibitor type 1 (PAI-1)ing PAI-1 synthesis. The fall in t-PA levels could be counteracted by
inhibiting t-PA degradation by either RAP or chloroquine. Interest- [7]. We and others have shown that inflammatory media-
ingly, chloroquine also quenched the TNFa-induced changes in t-PA tors such as tumor necrosis factor a (TNFa) and inter-
and PAI-1 mRNA levels. Using TNFa mutants and agonistic or
leukin-1 suppress t-PA production and increase PAI-1blocking monoclonal antibodies specific for the TNF receptors p55
and p75, we found evidence that chloroquine interfered with the activa- synthesis by HMCs [7, 8], which is in accord with the
tion of the TNF receptor p55 and/or its intracellular signaling route. diminished fibrinolytic activity observed in the peritoneal
Conclusions. Receptor-mediated endocytosis plays a crucial role in
cavity during inflammatory episodes [2]. We now reportregulating the fibrinolytic capacity of HMCs by its participation in the
degradation of t-PA and u-PA, and in the TNFa-induced decrease in that HMCs not only actively synthesize PAs, but also
t-PA and the increase in PAI-1 expression. very efficiently internalize and degrade t-PA and u-PA via
receptor-mediated endocytosis. This is clearly different
from the plasma situation in which, for example, t-PA
Continuous ambulatory peritoneal dialysis (CAPD) is is mainly derived from the vascular endothelium, but is
based on the selective changes that occur across the large cleared predominantly by the liver via the mannose recep-
tor, localized primarily on liver endothelial cells [9, 10]
and the low-density lipoprotein receptor–related proteinReceived for publication January 26, 1998
(LRP) expressed by liver parenchymal cells [11, 12].and in revised form June 30, 1998
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in HMCs in culture under basal as well as inflammatory tained from Boehringer Ingelheim (Ingelheim, Germany).
Ukidan two-chain u-PA was purchased from Seronoconditions. We identified the receptors expressed in
HMCs by Northern and ligand-blot analyses and studied (Aubonne, Switzerland). GST-RAP, used for inhibition
studies, was prepared at our laboratory by Dr. J.H. Ver-their interaction with 125I-labeled t-PA and u-PA. We
have used specific inhibitors, including a 39 kDa LRP heijen using the Salmonella japonicum glutathione-S-
transferase (GST)-RAP expression plasmid, kindly pro-copurifying protein, also termed receptor-associated
protein (RAP) [13, 14], a u-PA receptor blocking mono- vided by Dr. J. Herz (University of Texas Southwestern
Medical Center, Dallas, TX, USA) [13]. The u-PA recep-clonal antibody, and chloroquine, an inhibitor of the
lysosomal pathway [15], to evaluate the consequences tor blocking monoclonal antibody H-2 was a kind gift
from Dr. U. Weidle (Boehringer Mannheim, Penzberg,of inhibition of receptor-mediated endocytosis on the
accumulation of t-PA and u-PA in the medium of control Germany). D-mannose, chloroquine, bovine serum albu-
min (BSA), and Tween 80 were purchased from Sigmaand TNFa-treated HMCs. Interestingly, we found that
inhibition of endocytosis by chloroquine not only blocked (St. Louis, MO, USA). Hybond-N1 filters, Hyperfilm
MP, deoxycytidine 5 [a-32P] triphosphate (3 mCi/mmol)t-PA and u-PA degradation but also TNFa action. To
explore whether this latter effect is related to TNFa or and Na125I-iodine were obtained from Amersham (Buck-
inghamshire, UK). Other materials used have been speci-to (one of the two) TNFa receptors (TNFR-p55 and
TNFR-p75) [16], we used two TNFa mutants and an fied in the methods described or in the related references.
agonistic monoclonal antibody selectively binding to and
Cell culture experimentsactivating either the TNFR-p55 or the TNFR-p75 [17, 18].
Human peritoneal mesothelial cells were isolated from
the omental tissue of consenting patients undergoing
METHODS
elective surgery. Cells were grown in fibronectin-coated
M199 medium was obtained from Flow Laboratories dishes in M199 supplemented with 20 mmol/liter HEPES
(Irvine, UK); tissue culture plastics were from Costar (pH 7.4), 10% (vol/vol) human serum, 10% (vol/vol)
(Cambridge, MA, USA). A crude preparation of endo- heat-inactivated newborn calf serum, 150 mg/ml endothe-
thelial cell growth factor was prepared from bovine brain lial cell growth factor, 2 mmol/liter l-glutamine, 5 IU/
as described by Maciag et al [19]. Human serum was ml heparin, 100 U/ml penicillin, and 100 mg/ml strepto-
prepared from freshly collected blood of healthy donors, mycin at 378C in a 5% CO2–95% air atmosphere. The
pooled, and stored at 48C; it was not heat inactivated medium was replaced every two to three days. Subcul-
before use. Newborn calf serum was purchased from tures were obtained by trypsin/ethylenediaminetetraace-
Gibco (Grand Island, NY, USA); it was heat inactivated tic acid treatment of confluent monolayers at a split ratio
(30 min at 568C) before use. Sterile, pyrogen-free human of 1:3. Cells from omental tissue were pure mesothelial
serum albumin (20% wt/vol) was from the Central Labo- cells as assessed by their uniform cobblestone appear-
ratory of the Netherlands Red Cross Blood Transfusion ance at confluence, by the absence of von Willebrand
Service (Amsterdam, The Netherlands). Collagenase factor, and by the uniform positive staining for cytokera-
type II was from Worthington (Freehold, NY, USA). tins 8 and 18 and for vimentin [7]. For the experiments,
Human fibronectin was a gift from Dr. J.A. van Mourik, confluent cultures were used at the second or third pas-
Central Laboratory of the Netherlands Red Cross Blood sage, and cells were always refed the day before the
Transfusion Service. experiment with incubation medium: M199, supple-
Mouse monoclonal antibodies against cytokeratins 8 mented with 20 mmol/liter HEPES (pH 7.4), 10% (vol/
and 18 and against vimentin were a gift from Dr. G. vol) human serum, 2 mmol/liter l-glutamine, and antibi-
van Muijen (University of Nijmegen, The Netherlands). otics. Conditioned media were obtained by incubating
Human recombinant TNFa was a gift from Dr. J. Tav- cells in 2 cm2 dishes at 378C with 0.5 ml incubation me-
ernier (Biogent, Ghent, Belgium). The TNFa prepara- dium containing the appropriate concentration of the
tion contained 2.45 3 107 U/mg protein and less than test compound or stock solvent. The conditioned media
40 ng lipopolysaccharide/mg protein. The TNF mutant were centrifuged for five minutes at 8,000 r.p.m. in a
R32W-S86T-TNFa, which selectively binds and activates Microfuge centrifuge to remove cells and cellular debris.
the human TNFR-p55 and does not react with the human Conditioned media were stored at 2208C until use. The
TNFR-p75, the TNF mutant D143N-A145R-TNFa, which cells were used for isolation of RNA.
specifically recognizes the TNFR-p75, the antagonistic
Labeling of t-PA and u-PAmonoclonal antibody utr-1, specific for the TNFR-p75,
and the agonistic monoclonal antibody htr-9, specific for Tissue-type plasminogen activator and u-PA were la-
TNFR-p55, were a gift from Dr. W. Lesslauer (Hoffmann- beled with 125I using the iodogen method [20]. Polyethyl-
LaRoche, Basel, Switzerland) and have been previously ene vessels of 1.5 ml were coated with 10 mg iodogen.
Next, 10 mg t-PA or u-PA in 50 mmol/liter Tris-HCl, 0.25described [17, 18]. Recombinant t-PA (Actilyze) was ob-
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mol/liter 6-AHA, 1 mol/liter NaCl, pH 8, were incubated t-PA, u-PA, PAI-1, u-PA receptor, LRP, very low density
lipoprotein (VLDL) receptor, mannose receptor, and gly-with 0.5 mCi Na125I for 10 minutes at room temperature
in the vessels. The reaction mixture was transferred to ceraldehyde-3-phosphate dehydrogenase mRNA content
by Northern blot hybridization. With Northern blotting,another vessel containing an equal volume of 4 mg/ml
potassium iodide to avoid nonspecific binding of 125I to RNA samples are subjected to gel electrophoresis in form-
aldehyde-agarose gels, as outlined by Maniatis, Fritscht-PA. Labeled t-PA or u-PA was separated from free
125I using a 10 ml Sephadex G25 Coarse column (eluant and Sambrook [23]. After electrophoresis, RNA was
transferred to Hybond-N1 according to the manufactur-50 mmol/liter Tris-HCl, 0.01% (vol/vol) Tween 80, 1 mg/
ml BSA, pH 8). Labeling resulted in approximately 600 er’s instructions. Hybridization was usually performed
at 628C with 1 ng/ml probe labeled by random primecpm/fmol, with 80% recovery of t-PA or u-PA activity.
labeling (Multiprime; Amersham, Houten, The Nether-
Association and degradation of 125I-t-PA and 125I-u-PA lands) to approximately 2 3 108 cpm/mg DNA. The mem-
branes were subsequently exposed to Amersham Hyper-Cells (12-well plates) were washed once with phos-
phate-buffered saline (PBS), 1% (wt/vol) BSA, pH 4, to film-MP film with an intensifying screen at 2808C.
remove possible receptor ligands, and three times with
cDNA probesPBS, 1% (wt/vol) BSA, pH 7.4, 48C, and then incubated
with 125I-t-PA or 125I-u-PA, with or without inhibitors, in The following cDNA fragments were used as probes
in the hybridization experiments: a 1.9 kb Bgl II fragment500 ml M199, 1% (wt/vol) human serum albumin, 0.01%
(vol/vol) Tween 80, at 378C in a 5% CO2–95% air atmo- of human t-PA cDNA [24], a 2.5 kb EcoRI fragment of
human PAI-1 cDNA of the 3.1 kb transcript [25], a 6 kbsphere. After incubation, cell media were collected, and
trichloroacetic acid was added (final concentration 10% XhoI/EcoRI fragment of the human LRP cDNA [26], a
5.1 kb EcoRI/MluI fragment of the murine mannosewt/vol) to precipitate nondegraded 125I-t-PA or 125I-u-PA,
which was collected by centrifugation (10 min at 15,000 g). receptor cDNA [27], a 0.75 kb EcoRI fragment of the
human VLDL receptor cDNA [28], and a 1.2 kb PstITo eliminate the possibility that the cells might deiodi-
nate rather than degrade 125I-t-PA and 125I-u-PA, free 125I fragment of a rat glyceraldehyde-3-phosphate-dehydro-
genase cDNA provided by Dr. R. Offringa (Universitywas extracted. To the 500 ml trichloroacetic acid superna-
tant obtained as mentioned earlier here, 5 ml 40% (wt/ of Leiden, The Netherlands), which is commonly used
as an internal standard probe [29]. The pUK 0321 harbor-vol) KI and 25 ml 30% (vol/vol) H2O2 were added. After
five minutes, the free iodine was extracted with 800 ml ing a 1,023 bp fragment of the human u-PA cDNA was
a gift from Dr. W.D. Schleuning (Schering, Berlin, Ger-chloroform. The radioactivity of the remaining 125I-tyro-
sine (and possibly 125I-peptides) in the upper water layer many) [30]. Human u-PA receptor cDNA probe was
obtained from Drs. F. Blasi and K. Danø (Copenhagen,(five min at 15,000 g), containing degraded 125I-t-PA or
125I-u-PA, was determined. For the determination of cell- Denmark) [31].
associated radioactivity, the cells were washed twice with
Preparation of membrane fragments andPBS 0.1% (wt/vol) BSA and twice with PBS, lyzed with
ligand-blotting analysis1% (vol/vol) Triton X-100 for 15 minutes at room tem-
perature, and the radioactivity of the lysates was deter- Cells (75 cm2) were washed once with PBS, gently
scraped off the dish with a rubber policeman in the pres-mined. Association and degradation were corrected for
radioactivity determined in empty parallel wells (less ence of 2.5 ml 0.05% (wt/vol) ethylenediaminetetraacetic
acid, and, after addition of 7.5 ml culture medium, col-than 5%).
lected by centrifugation at 250 3 g for 10 minutes. Deter-
Assays gent extracts were prepared by solubilizing the cell pel-
lets in 0.1 ml PBS containing 0.1% (vol/vol) Triton X-100.The assay of t-PA antigen was performed with the
ELISA Thrombonostika t-PA (Organon-Teknika, Turn- After sonification (15 min in a Decon FS100 sonificator),
debris and nuclei were removed by centrifugation athout, Belgium) as described by Bos et al [21]. In this assay,
free t-PA and t-PA:PAI-1 complexes are detected with 1000 3 g for five minutes. The supernatants, containing
the membrane fragments, were stored at 2208C until use.equal efficiency. PAI-1 antigen was measured by ELISA
(Imulyze) obtained from Biopool (Umea˚, Sweden). Samples of membrane fragments were resolved by
SDS-PAGE in a 5% gel, using an SDS concentration of
RNA isolation and Northern blotting 0.1% (wt/vol). After electrophoresis, the proteins were
transferred electrophoretically to Protan nitrocelluloseTotal RNA was extracted from cells as described by
Chomczynski and Sacchi [22]. RNA samples were dis- filters (Schleicher and Schuell, Dassel, Germany) in a
buffer of 25 mmol/liter Tris, 190 mmol/liter glycine, pHsolved in H2O. The RNA concentration in each sample
was determined spectrophotometrically. Equal amounts 8.6, 20% (vol/vol) methanol and 0.1% (wt/vol) SDS, at
1 mA/cm2 overnight, using a Pharmacia-LKB semi-dryof RNA from different dishes were analyzed for their
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the degradation of 125I-t-PA (2 nmol/liter) to 9 6 4%
(mean 6 sd, N 5 3) and that of 125I-u-PA (2 nmol/liter)
to 74 6 6% (N 5 3). Similarly, the addition of a 100-fold
excess of u-PA (200 nmol/liter) reduced the degradation of
125I-u-PA to 14 6 12% (N 5 3) and that of 125I-t-PA to
51 6 13% (N 5 3). Addition of 100 mol/liter chloroquine,
a compound known to inhibit the lysosomal degrada-
tive route, reduced degradation of both 125I-t-PA and
125I-u-PA to below 15%.
Analysis of receptors involved in t-PA and u-PA
degradation in HMCs
Northern-blotting studies were conducted to examine
Fig. 1. Human mesothelial cells (HMCs) were incubated with 2 nmol/ the expression of the LRP, VLDL receptor, mannose
liter ligand for three hours at 378C. Degradation of 125I-t-PA (j) or 125I- receptor, and u-PA receptor mRNAs in HMCs under
u-PA (h) by the cells without (control) or with unlabeled t-PA (200
basal and inflammatory conditions (Fig. 2A). Transcriptsnmol/liter), unlabeled u-PA (200 nmol/liter) or chloroquine (100 mmol/
liter) was determined. Data are expressed as percentage values of con- for LRP (15 kb), the VLDL receptor (3.4 kb), and the
trols and are means 6 sd for three independent experiments in triplicate. u-PA receptor (1.4 kb) were evident in the cells before
and after a 24-hour exposure to 1,000 U/ml TNFa. After
TNF treatment, LRP and VLDL receptor mRNA concen-
trations were decreased to 77 6 26% (P 5 0.08; N 5 5)blot apparatus. The filters were blocked with 10 mmol/
and 55 6 14% (P 5 0.0007; N 5 5) of control values,
liter Tris, pH 7.5, with 145 mmol/liter NaCl, 1% (wt/vol)
respectively, whereas u-PA receptor mRNA levels in-
skim milk, and 0.05% (vol/vol) Tween-20 for 1.5 hours,
creased to 145 6 36% (P 5 0.025; N 5 5). The HMCs
followed by incubation with 125I-GST-RAP at a concen-
did not appear to express much, if any, mannose receptor
tration 2 nmol/liter, at room temperature for three hours (data not shown).
in 10 mmol/liter Tris, pH 7.5, 145 mmol/liter NaCl, 0.5% To biochemically confirm the presence of LRP and
(wt/vol) skim milk, and 0.05% (vol/vol) Tween-20. After VLDL receptor in HMCs, membrane preparations were
incubation, the filters were washed extensively with 30 electrophoresed and transferred to nitrocellulose filters
ml 10 mmol/liter Tris, pH 7.5, 145 mmol/liter NaCl, and and were tested for the presence of the receptors by
0.05% (vol/vol) Tween-20 for five minutes. Bound ligand incubating the filters with 125I-GST-RAP, which binds
was visualized by autoradiography. both receptors [13, 32]. Representative results are shown
in Figure 2B. We found the presence of predominantlyStatistics
binding activity comigrating with the LRP a-chain at a
Data are given as mean 6 standard deviation. Statisti- molecular weight of approximately 500,000.
cal analysis was performed with the nonparametric To learn more about the actual involvement of the
Mann-Whitney U-test, and a P value of less than 0.05 various receptors in the t-PA and u-PA degradation pro-
was considered significant. cess, we measured the degradation and cell-association
of 125I-t-PA and 125I-u-PA in the presence of GST-RAP
and D-mannose. The results shown in Figure 3A demon-RESULTS
strate that the addition of GST-RAP to the incubated
Degradation of 125I-t-PA and 125I-u-PA by HMCs cells inhibited in a concentration-dependent manner the
To determine the uptake and degradation of t-PA and degradation of 125I-t-PA and 125I-u-PA. At the highest
u-PA by HMCs, the cells were incubated with radiola- concentration (100 nmol/liter), the competitive effect of
beled 125I-t-PA (2 nmol/liter) or 125I-u-PA (2 nmol/liter) GST-RAP on the degradation of 125I-t-PA was as strong
for three hours at 378C, and degradation was assessed as the addition of excess unlabeled t-PA (89% vs. 91%
by measuring the release of 125I-tyrosine into the medium. inhibition). Less effect of GST-RAP was observed on
Degradation of t-PA ranged from 10 to 71 fmol/106 cells, the degradation of 125I-u-PA, in which degradation was
and that of radiolabeled u-PA from 7 to 16 fmol/106 cells reduced maximally to 35%. Parallel measurement of the
in three independent experiments using different HMC amount of cell-associated radiolabeled t-PA and u-PA
isolates. To find out whether the uptake of 125I-t-PA showed a very comparable picture (Fig. 3B). At the high-
and 125I-u-PA occurred via specific binding by the cells, est concentration of GST-RAP (100 nmol/liter), the re-
degradation of 125I-t-PA and 125I-u-PA in the presence of duction of cell-associated 125I-t-PA was similar to that
an excess of unlabeled t-PA or u-PA was studied (Fig. 1). seen in the presence of an excess (200 nmol/liter) of un-
labeled t-PA (84%). In agreement with the degradationAn excess of unlabeled t-PA (200 nmol/liter) reduced
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Fig. 2. Expression of low-density lipoprotein
receptor-related protein (LRP), very low density
lipoprotein (VLDL) receptor and urokinase-
type plasminogen activator (u-PA) receptor in
HMCs under basal conditions and after tumor
necrosis factor (TNFa; 1000 U/ml) exposure for
24 hours. (A) RNA was isolated and subject-
ed to Northern blot analysis using 32P-labeled
probes for LRP, VLDL receptor, u-PA receptor
and GAPDH. Signals for LRP, VLDL receptor
and u-PA receptor mRNA were quantitated by
densitometry and adjusted for the correspond-
ing GAPDH mRNA signals. Data are expressed
as relative values of TNFa-treated cells vs. con-
trol cells, and are means 6 sd for five indepen-
dent experiments. *P 5 0.025; **P 5 0.0007.
(B) Detergent extracts of control HMCs were
electrophoresed under nonreducing conditions
on SDS-polyacrylamide gels, transferred to ni-
trocellulose, and incubated with 125I-GST-RAP
(2 nmol/liter). A representative autoradiograph
is shown of an HMC extract (a) and a purified
LRP preparation (b).
studies, GST-RAP was less effective in lowering 125I-u-PA in the presence of GST-RAP (1 mmol/liter) or chloro-
association to HMCs (reduction to 76%), whereas unla- quine (300 mmol/liter) (Fig. 4A). As a result of the re-
beled u-PA (200 nmol/liter) reduced u-PA binding to duced degradation of t-PA, antigen levels were nearly
4%. This discrepancy suggests the presence of an addi- twofold higher in the media of cells incubated with GST-
tional u-PA clearing system in HMCs, which could obvi- RAP or chloroquine relative to those of untreated con-
ously not be blocked by GST-RAP. To determine whether trol cultures. PAI-1 antigen levels did not alter signifi-
this additional u-PA clearing system involves u-PA re- cantly in the presence of GST-RAP and were only
ceptor, we measured the degradation of 125I-u-PA after slightly decreased with chloroquine, indicating that the
addition of the u-PA receptor blocking monoclonal anti- increases in t-PA levels were not the result of a general
body H-2 (5 mg/ml). Similarly, as found with chloroquine, enhancement of protein synthesis.
H-2 reduced degradation of 125I-u-PA to below 15%, In contrast to t-PA, hardly any u-PA antigen was de-
indicating that the u-PA receptor has a central role in tectable in 24-hour conditioned medium of HMCs incu-
the various u-PA degradative routes (data not shown). bated under control conditions (Fig. 4B). The addition of
Even at a concentration of 100 mmol/liter, D-mannose either chloroquine (300 mmol/liter) or the u-PA receptor
could not block the degradation of either t-PA or u-PA
blocking antibody H-2 (5 mg/ml) increased u-PA levels(data not shown), confirming the absence of significant
in a representative experiment from 0.04 6 0.04 ng/105mannose receptor expression in HMCs. Previous experi-
cells in controls to 1.08 6 0.13 and 1.86 6 0.11 ng/105ments with liver endothelial cells have shown that this
cells in the presence of chloroquine and H-2, respec-concentration of D-mannose is sufficient to prevent deg-
tively. These findings confirm the critical role of u-PAradation of t-PA [33].
receptor in u-PA degradation but also illustrate the po-
Effect of GST-RAP, chloroquine, and H-2 on t-PA and tent u-PA degradative capacity of HMCs. GST-RAP,
u-PA accumulation in conditioned media of HMCs which increased t-PA accumulation as effectively as chlo-
roquine (Fig. 4A), prevented u-PA degradation to aNext, we measured t-PA antigen accumulation in the
conditioned media of HMCs after a 24-hour incubation much lesser extent, thus underlining the existence of
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Fig. 4. (A). Effect of 1 mmol/liter GST-RAP and 300 mmol/liter chloro-
quine on the accumulation of t-PA and PAI-1 in the conditioned media
of HMCs. HMCs were incubated for 24 hours with or without GST-RAP
or chloroquine, and the conditioned media assayed for the presence of
t-PA antigen (j) and PAI-1 (h). Data are expressed as percentage
values of controls and are means 6 sd of three independent experiments
in duplicate. (B) Effect of 1 mmol/liter GST-RAP, 300 mmol/liter chloro-
quine and 5 mg/ml u-PA receptor blocking antibody H-2 on the accumu-
Fig. 3. HMCs were incubated for three hours at 378C with 2 nmol/liter lation of u-PA in the conditioned media of HMCs. HMCs were incu-125I-t-PA or 125I-u-PA, and different concentrations of glutathione-S- bated for 24 hours with GST-RAP, chloroquine or H-2, and the
transferase–receptor associated protein (GST-RAP). Inhibition of t-PA conditioned media assayed for the presence of u-PA antigen. The data
( ) and u-PA ( ) degradation (A) and cell association (B) by GST- shown are from one representative experiment of three performed and
RAP was statistically significant (P < 0.05) from 6.25 nmol/liter onward. are expressed as means 6 sd of a triplicate experiment.
Data are expressed as percentage values of controls and are means 6
sd of three independent experiments in triplicate.
added simultaneously with TNFa (1,000 U/ml), chloro-
quine inhibited in a concentration-dependent manner
an additional, u-PA receptor-dependent u-PA clearing (100–300 mmol/liter) both the TNFa-evoked decrease in
system in HMCs. t-PA production and the TNFa-induced increase in
PAI-1 production (Fig. 5). This blocking effect of chlo-
Effect of chloroquine on t-PA and PAI-1 production and roquine on TNFa action could be confirmed at the
mRNA expression in control and TNFa-treated HMCs mRNA level (Fig. 6). No such effect was seen with GST-
In a previous study, we have shown that TNFa reduces RAP, which only counteracted the TNFa-induced de-
fibrinolytic activity of HMCs by increasing PAI-1 and crease in t-PA antigen by inhibiting degradation (data
decreasing t-PA synthesis [8]. In further experiments to not shown).
check whether inhibition of degradation by GST-RAP
Analysis of chloroquine inhibition of TNFa-actionor chloroquine could overcome the TNFa-induced de-
crease in t-PA synthesis in HMCs, we made the remark- To further characterize this quenching effect of chloro-
able finding that, apart from inhibiting t-PA degradation, quine on TNFa action, we first investigated which of the
two TNFa receptors, TNFR-p55 and TNFR-p75, mediateschloroquine also quenches the action of TNFa. When
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Fig. 6. Effect of chloroquine on t-PA and PAI-1 mRNA expression
in HMCs incubated in the presence of TNFa. HMCs were incubated
with or without TNFa (1000 U/ml) in the absence or presence of chlo-
roquine (300 mmol/liter), which was added 30 minutes prior to TNFa.
After 8 hours, RNA was isolated and subjected to Northern blot analysis
using 32P-labeled probes for t-PA, PAI-1 and GAPDH. This is a repre-
sentative experiment out of the three performed.
clonal antibody utr-1 (10 mg/ml), which blocks the TNFR-
p75 [18], was added simultaneously with wild-type TNFa
to HMCs, no changes in the effect of TNFa on t-PA and
PAI-1 production were observed (Fig. 7). Similarly, as
found with TNFa, chloroquine (300 mmol/liter) blocked
the effect of the mutant R32W-S86T-TNFa and that of
the agonistic antibody, htr 9, on t-PA and PAI-synthesis.
These results indicate that chloroquine interferes withFig. 5. HMCs were incubated for 24 hours at 378C with (h) or without
(j) 1000 U/ml TNFa and increasing concentrations of chloroquine the activation of the TNFR-p55 and/or its intracellular
(100 to 300 mmol/liter), which was added 30 minutes prior to TNFa. signaling route rather than with the TNFa molecule itself.The conditioned media were analyzed for t-PA antigen (A) and PAI-1
antigen (B). The data shown are from one representative experiment
of three performed and are expressed as mean values of a duplicate
experiment, with ranges indicated by error bars. DISCUSSION
This study provides evidence for the unique role of
the mesothelium in regulating the fibrinolytic capacity
of the peritoneal cavity. As part of its guard against thethe effect of TNFa on t-PA and PAI-1 expression in
unwanted adhesive obliteration of the cavity it lines, theHMCs. To that end, HMCs were incubated with the TNFa
mesothelium is well endowed with the ability to secretemutant, R32W-S86T-TNFa, which recognizes and stim-
t-PA and u-PA. Here, we demonstrate for the first timeulates TNFR-p55 only, and the TNFa mutant D143N-
that the fibrinolytic activity of HMCs is not only counter-A145R-TNFa, which specifically interacts with the
acted by the concomitant release of PAI-1 from the cells,TNFR-p75 [17]. Incubation of HMCs with R32W-S86T-
but also by rapid uptake and degradation of t-PA (andTNFa (40 ng/ml) for 24 hours induced comparable
u-PA) from the medium by receptor-mediated endocyto-changes in t-PA and PAI-1 antigen concentrations in
sis. This circulation-independent extravascular fibrino-the conditioned medium as wild-type TNFa, whereas
lytic system of the peritoneal cavity thus differs fromD143N-A145R-TNFa (40 ng/ml) showed no effect (Fig. 7).
the plasma fibrinolytic system, in which one cell typeThus, the sole stimulation of the TNFR-p55 was suffi-
(vascular endothelial cells) secretes t-PA and other cell-cient to stimulate PAI-1 and to decrease t-PA synthesis
types (liver hepatocytes, endothelial cells, and Kupfferin HMCs. This was confirmed with the agonistic mono-
cells) are responsible for t-PA clearance from the bloodclonal antibody, htr 9 (10 mg/ml), which specifically acti-
vates the TNFR-p55 [18]. In addition, when the mono- stream [10, 34]. Furthermore, our data suggest that re-
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Fig. 7. Effect of wild-type TNFa (40 ng/ml;
1000 U/ml); TNFa (40 ng/ml) and the antago-
nistic monoclonal antibody utr-1 (10 mg/ml),
which is specific for TNFR-p75; the TNFR-p75-
specific mutant D143N-A145R-TNFa (TNF-75;
40 ng/ml); the TNF-p55-specific mutant
R32W-S86T-TNFa (TNF-55; 40 ng/ml); the
monoclonal antibody htr-9 (10 mg/ml), which
activates the TNFR-p55; chloroquine (chlo;
300 mmol/liter); TNF55 (40 ng/ml) and chlo-
roquine (chlo; 300 mmol/liter); and htr-9 (10
mg/ml) and chloroquine (chlo; 300 mmol/liter)
on t-PA (j) and PAI-1 (h) antigen accumula-
tion in 24 hour conditioned medium of HMCs.
Data are expressed as percentage values of
controls and are means 6 sd of three indepen-
dent experiments.
ceptor-mediated endocytosis also participates in cyto- of u-PA to u-PA receptor, other GST-RAP–insensitive
mechanisms exist on HMCs that contribute to the inter-kine-mediated gene regulation, because the lysosomal
blocking agent chloroquine prevented both t-PA degra- nalization and degradation of u-PA.
Our finding that blocking of t-PA (and u-PA) endocy-dation and the antifibrinolytic action of TNFa in HMCs.
The major part of the binding and degradation of t-PA tosis in HMCs is an effective means of enhancing the
fibrinolytic capacity of these cells may be relevant forby HMCs is most likely mediated by LRP. This con-
clusion is based on these findings: (a) Degradation of preventing or treating adhesion formation. An adequate
fibrinolysis plays a crucial role in the controlled removal125I-t-PA is completely blocked by GST-RAP, whereas
no mannan-inhibitable degradation could be found, of fibrinous exudates from surfaces such as those of the
peritoneal cavity. If fibrin removal is not prompt, therewhich suggests that the clearance of t-PA is dependent
on the presence of one of the receptors of the LDL- is a fibroblastic invasion of the fibrin scaffolding, and
adhesions between opposing serosal surfaces may occurreceptor family. (b) Northern blot analysis and 125I-GST-
RAP ligand blotting demonstrate the expression of pre- [2, 3]. The fibrinolytic capacity of peritoneum is reduced
after inflammation, due to reduced t-PA and increaseddominantly LRP and only to a minor extent VLDL re-
ceptor. GST-RAP also inhibited the cell association and PAI-1 levels, and such a peritoneal hypofibrinolysis is
assumed to be a central denominator of adhesions fol-degradation of 125I-u-PA in HMCs, albeit much less effec-
tively than in the case of 125I-t-PA, suggesting that only lowing surgery or peritonitis in CAPD patients [39]. Fu-
ture therapeutic interventions aimed at overcoming thispart of the cellular catabolism of u-PA is by the LRP as
well. Although both LRP and the VLDL receptor are limiting fibrinolytic capacity could be based on inhibition
of t-PA (and u-PA) clearance by the mesothelium. Suchable to mediate the cellular uptake of pro-u-PA directly,
much less pro-u-PA is internalized by either receptor approaches could consist of antagonists such as RAP or
antibodies against the t-PA binding site of the LRP orwhen compared with u-PA-PAI-1 complexes [35, 36].
Pro-u-PA and u-PA accumulation on cell surfaces is compounds inhibiting endocytosis, such as the lysosomo-
tropic agent chloroquine. Our results are also relevantthought to be mainly mediated by the specific receptor,
u-PA receptor [37]. This receptor, also present on HMCs in the case of direct topical application of recombinant
t-PA to prevent adhesion formation: t-PA mutants lack-as demonstrated in this study, facilitates activation of
pro-u-PA to (two-chain) u-PA, and u-PA receptor-bound ing a binding affinity for the LRP receptor may be ex-
pected to be effective at much lower doses.u-PA is susceptible to inhibition by PAI-1. Whereas en-
docytosis of u-PA receptor-bound pro-u-PA and u-PA In addition to inhibiting t-PA degradation, another
beneficial use of chloroquine (and possibly other inhibi-is very slow, mechanisms exist for the endocytosis and
degradation of u-PA receptor-bound u-PA-PAI-1 com- tors of receptor-mediated endocytosis) may be a concomi-
tant quenching of TNFa-induced suppression of t-PA syn-plex via LRP and VLDL receptor [38]. However, it is
apparent from our experiments that after the binding thesis and increase of PAI-1 synthesis. A role for receptor-
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